Jun 04, 2018
ACGT Fellow and Scientific Advisory Council Member, Dr. Carl June, talks about making the next generation of CAR T therapies more potent and safer for patients. These include combination therapies for solid tumors and treatments with less toxic side effects. “Cure is a big word,” he remarks. The goal with cell and gene therapies was never to shoot “layups” but rather to score “three-pointers.”
Dr. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. He is currently director of the Center for Cellular Immunotherapies and director of Translational Research in the Abramson Cancer Center of the University of Pennsylvania, and is an investigator of the Abramson Family Cancer Research Institute.